Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 22, Issue 6, 2016, Pages 1442-1449

  Click, Benjamin ^a   Ramos Rivers, Claudia ^a   Koutroubakis, Ioannis E ^a   Babichenko, Dmitriy ^b   Anderson, Alyce M ^a   Hashash, Jana G ^a   Dunn, Michael A ^a   Schwartz, Marc ^a   Swoger, Jason ^a   Baidoo, Leonard ^a   Barrie, Arthur ^a   Regueiro, Miguel ^a   Binion, David G ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

cost; depression; inflammatory bowel disease; superuser

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OPIATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BLACK PERSON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROHN DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ICD-9; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MENTAL DISEASE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT BOWEL SYNDROME; TERTIARY CARE CENTER; ULCERATIVE COLITIS; UNEMPLOYMENT; ADOLESCENT; AFRICAN AMERICAN; AGED; ANUS DISEASE; COMORBIDITY; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; PATHOLOGY; REGISTER; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ANALGESICS, OPIOID; ANUS DISEASES; COLITIS, ULCERATIVE; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; FEMALE; HEALTH RESOURCES; HUMANS; HYPERTENSION; MALE; MENTAL DISORDERS; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; UNEMPLOYMENT; YOUNG ADULT;

EID: 84970939973     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000763     Document Type: Article

References (39)

1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
3. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn?s disease. Am J Gastroenterol. 2008;103:154-161.
4. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn?s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
5. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42; quiz e30.
6. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn?s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-525.
7. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn?s disease. Am J Gastroenterol. 2000;95:524-530.
8. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn?s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
9. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn?s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319-328.
10. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31: 693-707.
11. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn?s disease: a payor perspective. Am J Gastroenterol. 2000;95: 1955-1960.
12. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309-317.
13. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn?s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261-1272.
14. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014; 63:72-79.
15. Robert Wood Johnson Foundation. Super-utilizer Summit: Common Themes from Innovative Complex Care Management Programs. Available at: http://wwwrwjforg/en/library/research/2013/10/super-utilizersummithtml. Accessed February 2013.
16. Hempstead K, Delia D, Cantor JC, et al. The fragmentation of hospital use among a cohort of high utilizers: implications for emerging care coordination strategies for patients with multiple chronic conditions. Med Care. 2014;52(suppl 3):S67-S74.
17. Mautner DB, Pang H, Brenner JC, et al. Generating hypotheses about care needs of high utilizers: lessons from patient interviews. Popul Health Manag. 2013;16(suppl 1):S26-S33.
18. Gawande A. Medical Report: The Hot Spotters-Can We Lower Medical Costs by Giving the Neediest Patients Better Care?. Available at: http:// www.newyorker.com/magazine/2011/01/24/the-hot-spotters. Accessed January 24, 2011.
19. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
20. Harvey RF, Bradshaw JM. A simple index of Crohn?s disease activity. Lancet. 1980;1:514.
21. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Int Med. 1989;110:353-356.
22. Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn?s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578.
23. Kaufman S, Ali N, DeFiglio V, et al. Early efforts to target and enroll high-risk diabetic patients into urban community-based programs. Health Promot Pract. 2014;15:62s-70s.
24. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohn?s Colitis. 2014;8:288-295.
25. De Silva SCM, Ma C, Prusinkiewicz M, et al. Predictors of complications following a colectomy for ulcerative colitis patients: a population-based study. Gut. 2009;58:A457.
26. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576-1582.
27. Roman AL, Munoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011;17:2723-2733.
28. Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric comorbidity is associated with increased risk of surgery in Crohn?s disease. Aliment Pharmacol Ther. 2013;37:445-454.
29. Faust AH, Halpern LF, Danoff-Burg S, et al. Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. Gastroenterol Hepatol. 2012;8:173-181.
30. Gandhi S, Jedel S, Hood MM, et al. The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. J Crohn?s Colitis. 2014;8:401-408.
31. Timmer A, Preiss JC, Motschall E, et al. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2011:Cd006913.
32. Mikocka-Walus A, Bampton P, Hetzel D, et al. Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial. BMC Gastroenterol. 2015;15:54.
33. Szigethy E, Youk AO, Gonzalez-Heydrich J, et al. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn?s disease. Inflamm Bowel Dis. 2015;21:1321-1328.
34. Hillson E, Dybicz S, Waters HC, et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J Occupa Environ Med. 2008;50:969-977.
35. Mulder BJ, Tzeng HM, Vecchioni ND. Preventing avoidable rehospitalizations by understanding the characteristics of ?frequent fliers?. J Nurs Care Qual. 2012;27:77-82.
36. Li J, Williams MV. Managing superutilizers-staying patient centered is the solution. J Hosp Med. 2015;10:765-766.
37. Althaus F, Paroz S, Hugli O, et al. Effectiveness of interventions targeting frequent users of emergency departments: a systematic review. Ann Emerg Med. 2011;58:41-52.e42.
38. Colombara F, Martinato M, Girardin G, et al. Higher levels of knowledge reduce health care costs in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:615-622.
39. Kumar GS, Klein R. Effectiveness of case management strategies in reducing emergency department visits in frequent user patient populations: a systematic review. J Emerg Med. 2013;44:717-729.